Form 4: Organon Director Alan Ezekowitz Boosts Stake with Phantom Stock Acquisition

Organon & Co. Director Alan Ezekowitz has increased his beneficial ownership in the company by acquiring 23,904.382 phantom stock units, bringing his total holdings to 62,702.653 units.

Summary

• Alan Ezekowitz, a Director at Organon & Co. (OGN), acquired 23,904.382 phantom stock units on June 13, 2025.
• Each phantom stock unit is economically equivalent to one share of Organon common stock, on a 1-for-1 basis.
• These units were granted under the Organon Non-Employee Director Savings Plan.
• The phantom stock units are payable in cash upon settlement after Mr. Ezekowitz's termination of service as a director, according to the Plan's terms.
• The acquisition price for these units was $10.04 per unit.
• Following this transaction, Mr. Ezekowitz's total beneficial ownership of phantom stock units is 62,702.653.
• This total includes units acquired through dividend reinvestment transactions on June 13, 2024, September 12, 2024, December 12, 2024, March 13, 2025, and June 12, 2025.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive. While it's a routine compensation grant and not a direct stock purchase, a director increasing their beneficial ownership, even through phantom stock, can be interpreted as a sign of continued confidence in the company's long-term prospects and alignment with shareholder interests.

Positives

• A director increasing their beneficial ownership, even through phantom stock, can signal continued confidence in the company's future performance.
• The acquisition is part of a structured plan (Non-Employee Director Savings Plan), indicating routine compensation and alignment with long-term company interests.

Negatives

• The acquired units are phantom stock, which are cash-settled and do not represent direct ownership of common shares, limiting direct shareholder alignment compared to equity ownership.
• The transaction is a grant under a plan, not an open-market purchase, which might be seen as a less strong signal of conviction than a personal cash investment.

Risks

• Phantom stock units do not carry voting rights, unlike common stock, which means the director's direct influence on corporate governance through voting remains unchanged.
• The value of phantom stock is tied to the company's common stock price, exposing the holder to market fluctuations without direct equity ownership.

Future Outlook

The document does not contain specific forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the general terms of the phantom stock plan which indicate cash settlement upon termination of service.

Industry Context

This filing represents a routine insider transaction, common in publicly traded companies where non-employee directors receive compensation in the form of equity-linked instruments like phantom stock. Such transactions are part of standard corporate governance practices aimed at aligning director interests with shareholder value, although phantom stock offers less direct alignment than common stock due to its cash-settled nature and lack of voting rights.

Comparison to Industry Standards

• This transaction is consistent with common compensation practices for non-employee directors in the pharmaceutical and biotechnology industries, where equity-based awards, including phantom stock or restricted stock units, are frequently used to incentivize long-term commitment and align interests with company performance.
• While specific comparable companies or projects are not mentioned, the use of phantom stock is a recognized method for providing equity exposure without issuing actual shares, often seen in companies managing share dilution or specific tax implications for directors.

Stakeholder Impact

• Shareholders: The increase in director's beneficial ownership, even through phantom stock, may be viewed as a positive signal of alignment, though the cash-settled nature means no direct voting rights or share dilution.

Next Steps

• The phantom stock units are payable in cash upon the reporting person's termination of service as a director, as per the terms of the Organon Non-Employee Director Savings Plan.

Key Dates

Keywords

Organon & Co., OGN, SEC Form 4, Insider Transaction, Beneficial Ownership, Phantom Stock, Director Compensation, Alan Ezekowitz, Equity Compensation, SEC Filing